A Significant Shift in Obesity Treatment Recent clinical trial data has shed light on a potential new benefit for semaglutide (marketed as Wegovy). According to findings released by Novo Nordisk, the medication has demonstrated a remarkable ability to reduce liver fat in adults living with obesity and excess liver fat. The Findings at a Glance…